1. Home
  2. BSVN vs FHTX Comparison

BSVN vs FHTX Comparison

Compare BSVN & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bank7 Corp.

BSVN

Bank7 Corp.

HOLD

Current Price

$44.85

Market Cap

384.9M

Sector

Finance

ML Signal

HOLD

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

HOLD

Current Price

$4.84

Market Cap

332.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BSVN
FHTX
Founded
2004
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
384.9M
332.2M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
BSVN
FHTX
Price
$44.85
$4.84
Analyst Decision
Buy
Strong Buy
Analyst Count
3
8
Target Price
$53.33
$11.50
AVG Volume (30 Days)
8.1K
139.9K
Earning Date
04-14-2026
05-13-2026
Dividend Yield
2.52%
N/A
EPS Growth
N/A
25.32
EPS
4.50
N/A
Revenue
N/A
$30,909,000.00
Revenue This Year
$4.59
$7.81
Revenue Next Year
$7.19
$17.72
P/E Ratio
$9.54
N/A
Revenue Growth
N/A
36.75
52 Week Low
$33.92
$3.27
52 Week High
$50.10
$6.95

Technical Indicators

Market Signals
Indicator
BSVN
FHTX
Relative Strength Index (RSI) 67.28 46.68
Support Level $42.53 $4.42
Resistance Level $45.57 $5.85
Average True Range (ATR) 0.78 0.29
MACD 0.48 0.02
Stochastic Oscillator 64.64 58.24

Price Performance

Historical Comparison
BSVN
FHTX

About BSVN Bank7 Corp.

Bank7 Corp is a full-service commercial bank focused on providing customers with exceptional service and meeting their banking needs through a variety of commercial and retail financial services. It offers deposit banking products, including commercial deposit services, commercial checking, money market, and other deposit accounts, and retail deposit services such as certificates of deposit, money market accounts, checking accounts, negotiable order of withdrawal accounts, savings accounts, and automated teller machine access. etc. It generates revenues from interest income from financial instruments and non-interest income and service charges on deposit accounts.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: